BEND, Ore.--(BUSINESS WIRE)--BiomarkerBase™ 2.0 now includes every validated biomarker in clinical use, along with a significantly improved user interface and expanded functionality. The team at Amplion Research, publishers of BiomarkerBase™, manually reviewed every IVD test cleared or approved by the FDA since 2000, adding to the extensive set of test, drug, and clinical trial data already included in the database.
“Being aware of all existing clinical applications for molecular biomarkers is an important part of the groundwork for biomarker development projects,” said Adam Carroll, Ph.D., Science Director at Amplion Research. “Our primary goal has always been to give our clients confidence that they have in front of them the complete set of validated clinical biomarkers. To achieve that goal, there is no substitute for manual curation of the data,” said Carroll. “Additionally, all of the linkages between biomarkers and the specific tests, drugs, and trials that define them were each individually reviewed, making BiomarkerBase™ a very robust reference tool.”
Data Enhancements
Along with every validated clinical biomarker, the database also includes every emerging clinical biomarker disclosed in a phase 3 or 4 clinical trial, and will soon include all phase 1 and 2 trials as well. BiomarkerBase™ also now includes publications in its dataset for the first time, and most biomarkers in the database include the total number of published clinical studies for each biomarker, with full publication details for the 10 most recent. Additional enhancements to published clinical data and data from other sources are already in progress.
Interface Enhancements
Biomarkers can now be browsed by target, disease, drug, company, or therapeutic area, and every IVD test, drug label, and clinical trial that includes the biomarker is listed, with direct links to the primary records at FDA and NIH. BiomarkerBase™ has a clean and intuitive interface that makes browsing biomarkers and their related information fast. The database is, at the same time, very well connected, both internally and externally, making it easy to follow the key links between different information types.
Stakeholders in biomarker projects at drug companies, diagnostics companies, contract research organizations, technology transfer offices, and investment firms are all using BiomarkerBase™ to stay on top of every clinical application for a molecular biomarker; every drug label that includes a biomarker; and every clinical trial that includes a disclosed biomarker.
About Amplion Research Inc.
Amplion Research develops business intelligence resources that inform investments in molecular biomarkers and personalized medicine. Along with BiomarkerBase™, Amplion also publishes research reports, such as the recently released: “Regulatory and Market Trends for Biomarker-Based IVD Tests (2003-2012),” published April, 2013.
